Guangzhou Innogen Pharmaceutical Group Co Ltd (hkse:02591) Share Price

Company Profile

Business description
Guangzhou Innogen Pharmaceutical Group Co Ltd is a company in Asia to commercialize an innovative, humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It has commercialized Efsubaglutide Alfa (brand name: Diabegone), its Core Product, for the treatment of type 2 diabetes (T2D) in China. Its core business model is to discover, develop and commercialize innovative therapies for diabetes and other metabolic diseases. The company has built a pipeline of drug candidates targeting diabetes and other metabolic diseases.
Contact
No. 2 Tengfei Second Street
Room 409, Building H Self-numbered Creative Building
China-Singapore Guangzhou Knowledge City
Huangpu District, Guangdong Province
Guangzhou
CHN
https://www.innogenpharm.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
96

Recommended

Siteminder’s newly released product for hotel owners and travel agents could widen its moat and see revenue accelerate further.

Joseph Taylor | 16 September 2025

Working to prevent repeated failures could also improve competitiveness.

Nathan Zaia | 15 September 2025

Acquisition unlikely to improve prospects in the US and detracts from other opportunities.

Roy Van Keulen | 15 September 2025

Index	Last price	Change	% Change
All Ordinaries	9,151.20	1.30	-0.01%
CAC 40	7,836.15	60.78	-0.77%
DAX 40	23,458.89	289.97	-1.22%
Dow JONES (US)	45,684.25	199.20	-0.43%
FTSE 100	9,204.45	72.58	-0.78%
HKSE	26,438.51	8.05	-0.03%
NASDAQ	22,348.87	0.12	0.00%
Nikkei 225	44,902.27	134.15	0.30%
NZX 50 Index	13,234.89	26.58	0.20%
S&P 500	6,608.02	7.26	-0.11%
S&P/ASX 200	8,877.70	3.00	-0.03%
SSE Composite Index	3,861.86	1.36	0.04%